Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment

Market Focus

Yesterday

On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.

The rally was driven by a combination of robust interim financial results and a fresh drug approval. The company reported H1 revenue of RMB 8.618 billion, up 44.8% year-over-year, with adjusted net profit reaching RMB 1.704 billion, a 40.5% increase. Product revenue surged 56.7% to RMB 8.201 billion, accounting for over 95% of total revenue. Operating cash flow soared over tenfold to RMB 3.588 billion, highlighting significantly improved earnings quality.

Meanwhile, China's NMPA approved Jaypirca (pirtobrutinib) as monotherapy for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, expanding the company's oncology portfolio. Multiple international investment banks, including Nomura, Daiwa, Jefferies, and BOCOM International, have recently raised their target prices while maintaining buy ratings. Management has guided for RMB 20 billion in product sales by 2027 and RMB 35-40 billion in total revenue by 2030, reinforcing long-term growth confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1150331675"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150331675\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150331675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150331675","market":"hk","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment","media":"Market Focus","content":"<p><p>On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.</p><p>The rally was driven by a combination of robust interim financial results and a fresh drug approval. The company reported H1 revenue of RMB 8.618 billion, up 44.8% year-over-year, with adjusted net profit reaching RMB 1.704 billion, a 40.5% increase. Product revenue surged 56.7% to RMB 8.201 billion, accounting for over 95% of total revenue. Operating cash flow soared over tenfold to RMB 3.588 billion, highlighting significantly improved earnings quality.</p><p>Meanwhile, China's NMPA approved Jaypirca (pirtobrutinib) as monotherapy for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, expanding the company's oncology portfolio. Multiple international investment banks, including Nomura, Daiwa, Jefferies, and BOCOM International, have recently raised their target prices while maintaining buy ratings. Management has guided for RMB 20 billion in product sales by 2027 and RMB 35-40 billion in total revenue by 2030, reinforcing long-term growth confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.</p><p>The rally was driven by a combination of robust interim financial results and a fresh drug approval. The company reported H1 revenue of RMB 8.618 billion, up 44.8% year-over-year, with adjusted net profit reaching RMB 1.704 billion, a 40.5% increase. Product revenue surged 56.7% to RMB 8.201 billion, accounting for over 95% of total revenue. Operating cash flow soared over tenfold to RMB 3.588 billion, highlighting significantly improved earnings quality.</p><p>Meanwhile, China's NMPA approved Jaypirca (pirtobrutinib) as monotherapy for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, expanding the company's oncology portfolio. Multiple international investment banks, including Nomura, Daiwa, Jefferies, and BOCOM International, have recently raised their target prices while maintaining buy ratings. Management has guided for RMB 20 billion in product sales by 2027 and RMB 35-40 billion in total revenue by 2030, reinforcing long-term growth confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1150331675","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150331675","pubTimestamp":1790735980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.The rally was driven by a combination of robust interim financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"走势提醒|信达生物常规交易上涨3.18%，强劲的中期业绩和新药获批提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On September 30, INNOVENT BIO rose 3.18% in regular trading, trading at 98.85 HKD/share, with turnover of HKD 534 million.The rally was driven by a combination of robust interim financial results and a fresh drug approval. The company reported H1 revenue of RMB 8.618 billion, up 44.8% year-over-year, with adjusted net profit reaching RMB 1.704 billion, a 40.5% increase. Product revenue surged 56.7% to RMB 8.201 billion, accounting for over 95% of total revenue. Operating cash flow soared over tenfold to RMB 3.588 billion, highlighting significantly improved earnings quality.Meanwhile, China's NMPA approved Jaypirca (pirtobrutinib) as monotherapy for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, expanding the company's oncology portfolio. Multiple international investment banks, including Nomura, Daiwa, Jefferies, and BOCOM International, have recently raised their target prices while maintaining buy ratings. Management has guided for RMB 20 billion in product sales by 2027 and RMB 35-40 billion in total revenue by 2030, reinforcing long-term growth confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}